Déjà Vu for breast cancer two?

Journal of the National Cancer Institute

Volumn 96, Issue 7, 2004, Pages 497-499

  Stearns, Vered ^a   Davidson, Nancy E ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR ALPHA; PROGESTERONE RECEPTOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR; TUMOR MARKER;

ADULT; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; EDITORIAL; FEMALE; HISTOPATHOLOGY; HUMAN; INDIVIDUALIZATION; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; OSTEOPOROSIS; PATIENT CARE; PHENOTYPE; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; THEORY; TREATMENT OUTCOME; AGE; BREAST TUMOR; CHEMISTRY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; INCIDENCE; MIDDLE AGED; MULTIPLE CANCER; NEOPLASM; NOTE; PATHOLOGY; PREDICTION AND FORECASTING; SECOND CANCER; SURVIVAL;

AGE FACTORS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; NEOPLASMS, MULTIPLE PRIMARY; NEOPLASMS, SECOND PRIMARY; PREDICTIVE VALUE OF TESTS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 1842833561     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh119     Document Type: Editorial

References (23)

1. Swain SM, Wilson JW, Mamounas EP, Bryant J, Wickerham DL, Fisher B, et al. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst 2004; 96:516-23.
2. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;30:96-102.
3. Fisher B, Anderson S, Wickerham D, DeCillis A, Dimitrov N, Mamounas E, et al. Increased intensification and total dose of cyclohosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from NSABP B-22. J Clin Oncol 1997;15:1858-69.
4. Fisher B, Anderson S, DeCillis A, Dimitrov N, Atkins JN, Fehrenbacher L, et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 1999;17:3374-88.
5. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998; 352:930-42.
6. Lippman ME, Allegra JC, Thompson EB, Simon R, Barlock A, Green L, et al. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 1978;298:1223-8.
7. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-9.
8. Colleoni M, Minchella I, Mazzarol G, Nole F, Peruzzotti G, Rocca A, et al. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol 2000; 11: 1057-9.
9. Albain KS, Green SJ, Ravdin PM, Cobau CD, Levine EG, Ingle JN, et al. Adjuvant chemohormonal therapy for primary should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). Proc ASCO 2002;21:143a.
10. Allred D, Bryant J, Land S, Paik S, Fisher E, Julian T, et al. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: findings from NSABP Protocol B-24. Breast Cancer Res Treat 2002;76:30a.
11. Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353:1993-2000.
12. Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 2003;362:95-102.
13. Arpino G, Weiss H, Hilsenbeck S, Osborne K. The hormone receptor status of a contralateral breast cancer is independent of the first primary in patients not receiving adjuvant systemic therapy. Breast Cancer Res Treat 2003;82 (1 Suppl):256a.
14. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296-300.
15. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-97.
16. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses .Cancer 2003;98: 1802-10.
17. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349: 1793-802.
18. Rutqvist LE, Cedermark B, Glas U, Mattsson A, Skoog L, Somell A, et al. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst 1991;83:1299-306.
19. Fisher B, Anderson S, Tan-Chiu E, Wolmark N, Wickerham DL, Fisher ER, et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001;19:931-42.
20. Hutchins L, Green S, Ravdin P, Lew D, Martino S, Abeloff M, et al. CMF vs. CAF±tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: update of tamoxifen results. Breast Cancer Res Treat 1999;57:1a.
21. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
22. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
23. Berra Y. The Yogi Book: "I Really Didn't Say Everything I Said." 1998.